ArchiMed appoints three new partners
Healthcare-focused French GP ArchiMed has appointed Christophe Berthoux, Jean-Yves Desmottes and Mario Philips as partners.
Berthoux and Desmottes joined ArchiMed as operating partners, while Philips joined the firm as a strategic partner.
Prior to joining ArchiMed, Berthoux was CEO of UK-based Synexus, a provider of drug research support services and patient recruitment for clinical trials. He also worked as US-based global head of sales and marketing for Charles River Laboratories.
Berthoux will continue in his current non-executive chairman role at venture-capital-backed Imaging Analysis Group, which uses imaging technology and artificial intelligence to streamline the development of medical treatments.
Prior to joining ArchiMed, Desmottes was general manager of biology-based skincare solutions group Bioderma Dermatological Laboratories. He also served as vice-president in charge of operations at Bioderma's parent, Naos Group, and worked at PwC, where he advised on mergers, acquisitions and restructurings in the healthcare sector.
Philips is the non-executive chairman of ArchiMed portfolio company Clean Biologics, a specialist in safety testing for biopharmaceuticals. In March, he also became CEO of PolyneuroS, a developer of kits for the diagnosis and follow-up treatment of neurodegenerative conditions. As a strategic partner at ArchiMed, he will continue in his positions at both PolyneuroS and Clean Biologics.
ArchiMed is a private equity firm targeting companies based in Europe and North America, and operating in the biopharma, medtech, diagnostics, life sciences, healthcare IT, consumer health, public safety and care services sectors. Its international team combines investment, medical, technological and operational experience.
The firm is currently investing via its Med II fund, which closed on €315m in September 2017. The vehicle deploys equity tickets in the €5-50m range.
ArchiMed recently exited Italian dental group Primo, which was a portfolio company of its Med I fund, reaping a 3x return on the investment.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









